🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · Real-Time Price · USD
2.230
-0.120 (-5.11%)
Nov 20, 2026, 4:00 PM EST - Market closed

Company Description

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada.

The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer.

It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products.

In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications.

Sunshine The company is based in Fort Lauderdale, Florida.

Sunshine Biopharma, Inc.
Sunshine Biopharma logo
CountryUnited States
Founded2006
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees50
CEOSteve Slilaty

Contact Details

Address:
333 Las Olas Way, CU4 Suite 433
Fort Lauderdale, Florida 33301
United States
Phone954 330 0684
Websitesunshinebiopharma.com

Stock Details

Ticker SymbolSBFM
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code1402328
CUSIP Number867781882
ISIN NumberUS8677818820
Employer ID20-5566275
SIC Code2834

Key Executives

NamePosition
Dr. Steve N. Slilaty Ph.D.Chairman, President and Chief Executive Officer
Camille SebaalyChief Financial Officer, Secretary and Director
Michel RoyChief Commercial Officer

Latest SEC Filings

DateTypeTitle
Nov 18, 2026S-1General form for registration of securities under the Securities Act of 1933
Nov 13, 2026DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 12, 202610-QQuarterly Report
Nov 12, 2026DEF 14AOther definitive proxy statements
Nov 10, 2026SCHEDULE 13G/AFiling
Oct 27, 2026DEF 14CFiling
Oct 14, 2026PRE 14CFiling
Oct 14, 20268-KCurrent Report
Oct 14, 2026SCHEDULE 13GFiling
Oct 13, 2026SCHEDULE 13GFiling